C4 therapeutics reports third quarter 2023 financial results and recent business highlights

Portfolio decision to prioritize ongoing phase 1/2 trials of cft7455, an ikzf1/3 degrader, and cft1946, a braf v600 degrader
CCCC Ratings Summary
CCCC Quant Ranking